We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fatality Risks Do Not Prevent FDA From Returning Tysabri to Market
Fatality Risks Do Not Prevent FDA From Returning Tysabri to Market
June 9, 2006
The FDA is making the “rare” decision to allow a drug to be sold after the product was pulled from the market due to serious health concerns because the benefits outweigh fatality risks, an official said.